Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wearable Electronic Devices | 7 | 2024 | 79 | 2.970 |
Why?
|
| Substance-Related Disorders | 8 | 2024 | 757 | 2.630 |
Why?
|
| Cannabis | 3 | 2023 | 54 | 2.070 |
Why?
|
| Telemedicine | 5 | 2024 | 379 | 1.910 |
Why?
|
| Opioid-Related Disorders | 10 | 2024 | 532 | 1.860 |
Why?
|
| Drug Overdose | 7 | 2025 | 123 | 1.620 |
Why?
|
| Craving | 3 | 2024 | 38 | 1.580 |
Why?
|
| Cannabinoids | 3 | 2023 | 41 | 1.570 |
Why?
|
| Analgesics, Opioid | 10 | 2024 | 533 | 1.510 |
Why?
|
| Substance Abuse Detection | 3 | 2016 | 39 | 1.360 |
Why?
|
| Fat Emulsions, Intravenous | 4 | 2015 | 36 | 1.310 |
Why?
|
| Acute Pain | 3 | 2024 | 20 | 1.110 |
Why?
|
| Biosensing Techniques | 5 | 2017 | 126 | 1.070 |
Why?
|
| Stress, Psychological | 2 | 2024 | 475 | 1.070 |
Why?
|
| Mobile Applications | 5 | 2024 | 142 | 1.060 |
Why?
|
| Seizures | 2 | 2025 | 141 | 1.000 |
Why?
|
| Cocaine | 4 | 2015 | 101 | 1.000 |
Why?
|
| Monitoring, Ambulatory | 3 | 2016 | 57 | 0.990 |
Why?
|
| Machine Learning | 4 | 2024 | 197 | 0.940 |
Why?
|
| Explosive Agents | 1 | 2025 | 4 | 0.910 |
Why?
|
| Plastics | 1 | 2025 | 22 | 0.890 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2019 | 36 | 0.750 |
Why?
|
| Hallucinogens | 1 | 2022 | 13 | 0.720 |
Why?
|
| Toxicology | 2 | 2024 | 22 | 0.720 |
Why?
|
| Smartphone | 4 | 2024 | 75 | 0.700 |
Why?
|
| Circulating MicroRNA | 1 | 2019 | 6 | 0.620 |
Why?
|
| Acetaminophen | 1 | 2019 | 53 | 0.590 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 53 | 0.590 |
Why?
|
| Humans | 36 | 2025 | 65826 | 0.540 |
Why?
|
| Systems Integration | 1 | 2017 | 26 | 0.510 |
Why?
|
| Transducers | 1 | 2017 | 24 | 0.510 |
Why?
|
| Glass | 1 | 2017 | 23 | 0.510 |
Why?
|
| Emergency Service, Hospital | 9 | 2024 | 1163 | 0.500 |
Why?
|
| Male | 23 | 2025 | 31398 | 0.490 |
Why?
|
| Adult | 15 | 2025 | 17567 | 0.470 |
Why?
|
| Transcriptome | 1 | 2019 | 408 | 0.470 |
Why?
|
| Hemodynamics | 2 | 2013 | 253 | 0.450 |
Why?
|
| Secondary Prevention | 1 | 2016 | 165 | 0.450 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 81 | 0.440 |
Why?
|
| Social Media | 1 | 2017 | 129 | 0.430 |
Why?
|
| Research Design | 1 | 2017 | 590 | 0.400 |
Why?
|
| Pilot Projects | 7 | 2021 | 1029 | 0.400 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2013 | 17 | 0.400 |
Why?
|
| Epinephrine | 1 | 2013 | 46 | 0.390 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 71 | 0.380 |
Why?
|
| Young Adult | 5 | 2025 | 4878 | 0.380 |
Why?
|
| Naloxone | 3 | 2023 | 53 | 0.360 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2329 | 0.350 |
Why?
|
| Galvanic Skin Response | 3 | 2016 | 25 | 0.350 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 876 | 0.340 |
Why?
|
| Skin | 1 | 2015 | 436 | 0.340 |
Why?
|
| Biomedical Research | 3 | 2024 | 263 | 0.330 |
Why?
|
| Female | 17 | 2025 | 34414 | 0.320 |
Why?
|
| Middle Aged | 9 | 2024 | 18491 | 0.320 |
Why?
|
| Heart Rate | 3 | 2020 | 335 | 0.310 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 133 | 0.310 |
Why?
|
| Buprenorphine | 2 | 2023 | 199 | 0.310 |
Why?
|
| Financing, Government | 2 | 2020 | 31 | 0.310 |
Why?
|
| Pain Management | 2 | 2024 | 174 | 0.290 |
Why?
|
| Oxycodone | 2 | 2017 | 28 | 0.260 |
Why?
|
| Harm Reduction | 2 | 2025 | 34 | 0.250 |
Why?
|
| Faculty, Medical | 2 | 2019 | 202 | 0.250 |
Why?
|
| Emergency Medicine | 2 | 2020 | 195 | 0.250 |
Why?
|
| Child | 3 | 2022 | 4653 | 0.250 |
Why?
|
| Logistic Models | 2 | 2021 | 1274 | 0.250 |
Why?
|
| Biomarkers | 2 | 2024 | 1502 | 0.240 |
Why?
|
| Skin Temperature | 2 | 2016 | 19 | 0.240 |
Why?
|
| Fractures, Bone | 2 | 2017 | 138 | 0.230 |
Why?
|
| Wrist | 2 | 2016 | 39 | 0.230 |
Why?
|
| Self Report | 2 | 2020 | 395 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 626 | 0.220 |
Why?
|
| Adolescent | 3 | 2021 | 6367 | 0.220 |
Why?
|
| Anticonvulsants | 1 | 2025 | 104 | 0.220 |
Why?
|
| Benzodiazepines | 1 | 2025 | 107 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 859 | 0.210 |
Why?
|
| Sentinel Surveillance | 1 | 2024 | 19 | 0.210 |
Why?
|
| Military Personnel | 1 | 2025 | 111 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2025 | 145 | 0.200 |
Why?
|
| Dronabinol | 1 | 2023 | 31 | 0.200 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 119 | 0.200 |
Why?
|
| Random Allocation | 2 | 2013 | 200 | 0.190 |
Why?
|
| Rats | 4 | 2013 | 2005 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1720 | 0.190 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 143 | 0.190 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5830 | 0.190 |
Why?
|
| Research Support as Topic | 2 | 2019 | 42 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2020 | 117 | 0.180 |
Why?
|
| Psychometrics | 1 | 2024 | 396 | 0.180 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 8 | 0.180 |
Why?
|
| Mentors | 2 | 2020 | 118 | 0.180 |
Why?
|
| Cholinergic Antagonists | 2 | 2019 | 32 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 126 | 0.170 |
Why?
|
| Blood Pressure | 2 | 2013 | 537 | 0.160 |
Why?
|
| Decision Making | 1 | 2024 | 430 | 0.160 |
Why?
|
| Drug Users | 1 | 2021 | 29 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1291 | 0.160 |
Why?
|
| Aged | 5 | 2024 | 15141 | 0.160 |
Why?
|
| Eating | 1 | 2021 | 140 | 0.160 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 22 | 0.160 |
Why?
|
| Wireless Technology | 1 | 2020 | 14 | 0.160 |
Why?
|
| Time Factors | 2 | 2019 | 3778 | 0.150 |
Why?
|
| Research Personnel | 1 | 2020 | 82 | 0.150 |
Why?
|
| Medication Adherence | 2 | 2017 | 202 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 54 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 66 | 0.150 |
Why?
|
| Mindfulness | 1 | 2020 | 72 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 375 | 0.140 |
Why?
|
| United States | 5 | 2024 | 8190 | 0.140 |
Why?
|
| Efficiency | 1 | 2018 | 39 | 0.140 |
Why?
|
| Naltrexone | 1 | 2019 | 91 | 0.140 |
Why?
|
| Writing | 1 | 2018 | 44 | 0.140 |
Why?
|
| Medical Informatics Applications | 1 | 2017 | 13 | 0.130 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 244 | 0.130 |
Why?
|
| Music Therapy | 1 | 2017 | 15 | 0.130 |
Why?
|
| Telemetry | 1 | 2017 | 17 | 0.130 |
Why?
|
| Incidence | 1 | 2021 | 1432 | 0.130 |
Why?
|
| Alcoholism | 1 | 2020 | 329 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 995 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 67 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1117 | 0.120 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 101 | 0.120 |
Why?
|
| Prognosis | 1 | 2021 | 1792 | 0.120 |
Why?
|
| Forecasting | 1 | 2017 | 231 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 78 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 799 | 0.120 |
Why?
|
| Equipment Design | 1 | 2017 | 374 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 126 | 0.110 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2016 | 84 | 0.110 |
Why?
|
| Locomotion | 1 | 2016 | 111 | 0.110 |
Why?
|
| Motion | 1 | 2015 | 71 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2020 | 3339 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 142 | 0.110 |
Why?
|
| Registries | 1 | 2019 | 934 | 0.110 |
Why?
|
| Body Temperature | 1 | 2015 | 46 | 0.110 |
Why?
|
| Age Factors | 1 | 2019 | 1595 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2017 | 157 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2019 | 881 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1441 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 505 | 0.110 |
Why?
|
| Algorithms | 1 | 2020 | 1060 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6953 | 0.100 |
Why?
|
| Infant | 1 | 2019 | 1720 | 0.100 |
Why?
|
| Pain | 1 | 2017 | 400 | 0.100 |
Why?
|
| Anticholinergic Syndrome | 1 | 2013 | 1 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2013 | 8 | 0.100 |
Why?
|
| Atropine | 1 | 2013 | 13 | 0.100 |
Why?
|
| Sodium Chloride | 1 | 2013 | 65 | 0.100 |
Why?
|
| Animals | 5 | 2015 | 21489 | 0.100 |
Why?
|
| Antithrombins | 1 | 2013 | 16 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2019 | 2088 | 0.100 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2013 | 27 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2013 | 41 | 0.100 |
Why?
|
| Muscarinic Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 55 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 593 | 0.090 |
Why?
|
| Salvia | 1 | 2012 | 1 | 0.090 |
Why?
|
| Mitragyna | 1 | 2012 | 1 | 0.090 |
Why?
|
| Cyclohexylamines | 1 | 2012 | 4 | 0.090 |
Why?
|
| Cyclohexanones | 1 | 2012 | 4 | 0.090 |
Why?
|
| Alkaloids | 1 | 2012 | 8 | 0.090 |
Why?
|
| Kinetics | 1 | 2013 | 757 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2013 | 287 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 86 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 847 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2012 | 81 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2013 | 556 | 0.080 |
Why?
|
| Risk Factors | 1 | 2019 | 5471 | 0.070 |
Why?
|
| Massachusetts | 1 | 2015 | 2158 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2025 | 113 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5681 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2790 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 174 | 0.050 |
Why?
|
| Fever | 1 | 2024 | 67 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 110 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2023 | 26 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 329 | 0.050 |
Why?
|
| Community Health Services | 1 | 2023 | 127 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 33 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 401 | 0.040 |
Why?
|
| Hospitals | 1 | 2024 | 399 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 763 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2023 | 226 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1236 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2019 | 24 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 130 | 0.040 |
Why?
|
| Capsules | 1 | 2017 | 33 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2020 | 501 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 309 | 0.030 |
Why?
|
| Pain Perception | 1 | 2017 | 5 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2017 | 21 | 0.030 |
Why?
|
| Radio Waves | 1 | 2017 | 19 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 28 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 995 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 110 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 92 | 0.030 |
Why?
|
| Affect | 1 | 2017 | 132 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 344 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 394 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 603 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 337 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 376 | 0.030 |
Why?
|
| Bleeding Time | 1 | 2013 | 4 | 0.030 |
Why?
|
| Dabigatran | 1 | 2013 | 20 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 193 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 371 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 711 | 0.020 |
Why?
|